Montelukast Almus

Montelukast, the active ingredient in Montelukast Almus, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in both adult and pediatric patients. GNH USA supplies Montelukast Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory conditions. - Asthma (maintenance therapy): improves long‑term control of symptoms and reduces exacerbations. - Allergic rhinitis (seasonal or perennial): relieves nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort in the stomach area. - Cough: occasional irritation of the throat. - Dyspepsia: indigestion or upset stomach. - Fatigue: feeling unusually tired. - Nausea: sensation of needing to vomit.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Neutropenia: reduced white blood cell count. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Montelukast, consider the following safety measures. - Assess asthma control: ensure patient is stable on current therapy. - Monitor neuropsychiatric symptoms: watch for mood changes or depression. - Use caution in hepatic impairment: adjust use if liver disease is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Not for acute asthma attacks: do not replace rescue inhalers. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Montelukast exposure. - Concurrent leukotriene modifiers (e.g., zafirlukast, zileuton): increase risk of adverse effects.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine, sertraline): may heighten neuropsychiatric risk. - Theophylline: additive bronchodilator effect may require dose adjustment. - Antihistamines: potential for increased sedation. - Warfarin: possible alteration of anticoagulant effect, monitor INR.